Jazz Pharmaceuticals plc (JAZZ) income statement
JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$247.77+7.06 (+2.93%)
Close on Nov 18, 2026Market cap $16.08BP/E 80.7Yield –
Jazz Pharmaceuticals plc income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 9.0%
- Net margin
- 4.4%
- Return on equity, FY2025
- -8.5%
Financial strength
- Current ratio
- 1.82
- Debt to equity
- 1.33
- Debt to assets
- 46.4%
- Cash to current liabilities
- 80.4%
Valuation
- P/E ratio
- 80.7
- Price to sales
- 3.41
- Price to book
- 3.84
- Dividend yield
- –
See a number that looks wrong?